OOriginDrugmedicine records 中文

R&D & QUALITY

How to read global pharma's public R&D and quality material

Author: OriginDrug Editorial Team · Review: Medical Content Review Group · Published and reviewed: 2026-08-14

Public material from Roche, Pfizer, GSK, Novartis, Lilly, Johnson & Johnson, Takeda and Boehringer Ingelheim can illuminate methods, but it does not itself prove a product's effectiveness, quality or marketing status.

Read the complete chain

A medicine does not move directly from a promising molecule to a finished product. Public research material commonly describes disease biology and target hypotheses, discovery and candidate selection, non-clinical work, controlled clinical research, regulatory submissions, process development, supply and post-marketing monitoring. Each stage answers a different question.

Discovery tools guide; experiments decide

Human-relevant models, computation, automation and high-throughput screening can broaden hypotheses and improve prioritisation. A hit still needs reproducibility, developability, safety and progressively stronger evidence. A research video or corporate announcement is not evidence that a product is effective, high quality or authorised.

Use the source that fits the claim

Company material can explain how an organisation describes a platform or programme. Regulatory labels and databases are suited to checking the current status of a particular product. Peer-reviewed papers are suited to examining methods, results and limitations for a specific research question. Keep these evidence layers separate.

PRIMARY REFERENCE

Reference entry points